Acute myeloid leukemia (AML) is a disease of the elderly, affecting patients with a median age of 65 --70 years. Cytotoxic chemotherapy remains the mainstay of treatment in younger patients (often defined as those below the age of 60 years), but is associated with lower complete remission (CR) rates and greater toxicity in older patients (X60 years), resulting in poor long-term outcomes and a median overall survival (OS) of o1 year.
Recurrent DNMT3A gene mutations were recently discovered in AML, 5 --7 and are associated with worse outcomes. 6 --8 It has been reported that at least some DNMT3A mutations, including those at the mutational hotspot codon R882, impair the protein's methyltransferase activity. 5, 7 Although the biological mechanisms linking DNMT3A mutations to leukemogenesis are not yet fully understood, an obvious question from the clinical standpoint is whether DNMT3A mutations influence the response to treatment with hypomethylating agents. We therefore evaluated DNMT3A mutation status in a cohort of 46 predominantly older patients with previously untreated AML, who were enrolled in two clinical trials and received decitabine at an initial dose of 20 mg/m 2 i.v. over 1 h for 10 days, as described in detail earlier. 4 Patients received decitabine either as a single agent (n ¼ 39; clinicaltrials.gov identifier NCT00492401 (ref. 6) ) or in combination with bortezomib (0.7 --1.3 mg/m 2 i.v. on days 5, 8, 12 and 15; n ¼ 7; NCT00703300). All patients who had genomic DNA from pretreated bone marrow specimens available were included in this analysis. DNMT3A exons 18, 19, 21, 22 and 24 --26 (GeneBank accession number NM_175629), where approximately 90% of mutations are located, 6 were studied using PCR and direct sequencing. Patients were also characterized for FLT3-internal tandem duplications (FLT3-ITD) and tyrosine kinase domain mutations (FLT3-TKD), and mutations in NPM1, IDH1, IDH2, TET2 and CEBPA as reported previously. 9 --11 The median age of the entire cohort was 74 years (range, 32 --85 years; only one patient was aged younger than 60 years). Of the 46 patients, 17 had cytogenetically normal (CN-) AML, based on the analysis of at least 20 metaphases from bone marrow, and 29 had abnormal karyotypes. According to the European LeukemiaNet (ELN) reporting system for genetic changes in AML, 12 10 patients fell into the ELN Favorable genetic category. This included two patients with t(8;21), and eight patients with CN-AML who had CEBPA mutations or mutated NPM1 without FLT3-ITD. Nine patients belonged to the ELN Intermediate-I category (that is, CN-AML with wild-type CEBPA, and wild-type NPM1 with or without FLT3-ITD or mutated NPM1 with FLT3-ITD). Eleven patients fell into the ELN intermediate-II category (that is, had cytogenetic abnormalities not classified as favorable or adverse). Sixteen had adverse cytogenetic abnormalities as classified by the ELN, including 11 with a complex karyotype.
We found 8 DNMT3A mutations among the 46 patients (17%). Among them, six were missense mutations affecting the mutational hot spot codon R882 (3 patients with c.2645G4A; p.(R882H) and 3 with c.2644C4T; p.(R882C)). One patient had a nonsense mutation [c.1729A4T; p.(K577*)], and one had a splicesite mutation [c.2322 þ 1G4A; p.0?]. All eight mutations were predicted to be 'disease causing' by the MutationTaster algorithm, which evaluates the disease-causing potential of gene mutations based on analyses of evolutionary conservation, splicesite changes, loss of protein features and changes affecting the amount of mRNA. 13 The associations of DNMT3A mutations with baseline patient characteristics are reported in Table 1 . DNMT3A-mutated patients had a higher median white blood cell count than DNMT3A-wild 
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Abbreviations: ELN, European LeukemiaNet; FLT3-ITD, internal tandem duplication of the FLT3 gene; FLT3-TKD, tyrosine kinase domain mutation of the FLT3 gene; WBC, white blood count. a All patients except one were aged 60 years or older. In one patient, both an IDH1 mutation (p.R132H) and an IDH2 mutation (p.R140Q) were detected. P-values are from the Wilcoxon test for continuous data or Fisher's exact test for count data and not adjusted for multiple comparisons.
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www.nature.com/leu type patients (P ¼ 0.04). DNMT3A mutations occurred in all ELN genetic groups. DNMT3A mutations were significantly associated with NPM1 mutations (P ¼ 0.004), and we observed a trend towards a higher prevalence of FLT3-ITD among DNMT3A-mutated patients (P ¼ 0.07). None of the other gene mutations we studied was significantly associated with DNMT3A mutations.
Overall, the CR rate in this cohort was 41% (19/46). In total, 6 of 8 DNMT3A-mutated patients (75%) achieved CR, compared with 13 of 38 patients with wild-type DNMT3A (34%; P ¼ 0.05; Table 2 ). Notably, all five patients with mutated DNMT3A and mutated NPM1 achieved CR, a significantly better response rate than among the remaining patients with other genotypes (14/41 (34%); P ¼ 0.008). No other pretreatment patient characteristics or gene mutations were associated with response to decitabine ( Table 2 ). This included TET2 or IDH1/IDH2 mutations (considered separately or in combination), which were recently linked to aberrant DNA methylation patterns in AML. 14, 15 The median OS of patients with DNMT3A mutations was 15.2 months, compared with 11.0 months for patients with DNMT3A-wild type. This comparison is limited by the small number of DNMT3A-mutated patients and the difference did not reach statistical significance.
Our findings are based on a relatively small and heterogeneous patient cohort, and therefore must be interpreted cautiously. Nevertheless, we believe that our observations are provocative, because they support a potential link between DNMT3A gene mutations, altered DNMT3A activity and sensitivity to hypomethylating drugs. Previously, our group has shown that high levels of microRNA miR-29b, which targets DNMT3A, are significantly associated with response to decitabine in AML (P ¼ 0.02). Lower DNMT3A expression levels also showed a borderline (P ¼ 0.06) association with higher CR rate in decitabine-treated patients. 4 Taken together, our results suggest that AML patients whose leukemic blasts have low DNMT3A activity, either due to loss-offunction mutations or due to low gene expression, may benefit from treatment with hypomethylating agents. If further studies confirm that DNMT3A mutations identify a subgroup of AML patients who are likely to respond to decitabine treatment, this would represent an important advance for risk-adapted stratification of AML patients to epigenetics-targeting therapy. Letters to the Editor
